MediBeacon Inc.

MediBeacon Inc. is a medical technology company specializing in fluorescent tracer agents and transdermal detection technology for non-invasive physiological monitoring. The company's proprietary platform enables real-time measurement and monitoring of vital organ function through biocompatible fluorescent agents that are sensed through the skin via transdermal optical sensors. Primary clinical focus areas include nephrology (kidney function assessment via transdermal GFR measurement), gastroenterology (gut barrier permeability assessment), ophthalmology (fluorescent angiography for retinal vasculature visualization), and surgical applications (intraoperative visualization and identification of anatomical structures). MediBeacon's Transdermal GFR (TGFR) System received FDA PMA approval (P230019) and CE Mark for human clinical use. The company serves leading academic medical centers, research institutes, contract research organizations (CROs), and pharmaceutical companies globally for both preclinical research and clinical applications. MediBeacon maintains offices in St. Louis, Missouri (USA), Mannheim, Germany, and partnerships in Greater China through Huadong Medicine Co., Ltd.